Addressing
exhausted
T cells

KINETA_web_hp_redpoint

Addressing exhausted T Cells

KINETA_web_hp_redpoint

Anti-CD27 agonist mAb

Kineta is developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells in the tumor microenvironment.

It has been recently demonstrated that it is very difficult to reverse T cell exhaustion. As an alternative approach, Kineta is developing agonist antibodies to a receptor (CD27) present on naïve T cells circulating outside the tumor.

Kineta has nominated a clinical candidate out of a diverse set of anti-CD27 agonist antibody sequences. The nominated candidate is a fully human monoclonal antibody that has been observed to show low nM binding affinity to CD27 in humans. In in vitro studies, Kineta’s lead candidate antibodies demonstrate robust agonist activation of T cells and NK cells demonstrating the ability to potentiate new anti-tumor responses. Kineta plans to develop the drug as an intravenous infusion.

KINETA_web_hp_redpoint

Target

CD27 is a clinically validated drug target that is a member of the TNF receptor superfamily and plays a critical role in T-cell activation by providing a co-stimulatory signal together with its ligand CD70.  CD27 is highly expressed on naïve T cells and also provides a co-stimulatory signal for NK cell activation.

Anti-CD27 monoclonal antibodies activate and induce the maturation and migration of naïve T cells. CD27 activation also drives the diversification of the T cell repertoire, lowering the activation threshold of T cells against low affinity tumor antigens. Recent data also suggests that an agonist anti-CD27 antibody can activate important innate immune cell populations like natural killer (‘‘NK’’) cells and inflammatory myeloid cells. These cells contribute to an effective anti-tumor response, especially in checkpoint inhibitor (CPI) resistant patients. Recent publications have also demonstrated that anti-CD27 agonist antibodies can drive tumor growth inhibition as a monotherapy and in combination with CPIs.

KINETA_web_hp_redpoint

Publications

Kineta CD27 Poster Presentation at AACR Conference on Tumor Immunology and Immunotherapy

Shawn Iadonato, Jessica Cross, Nathan Eyde, Emily Frazier, Neda Kabi, Chen Katz, Remington Lance, Kurt Lustig, Yulia Ovechkina, David Peckham, Shaarwari Sridhar, Carla Talbaux, Isabelle Tihista, Mei Xu, and Thierry Guillaudeux



Kineta CD27 Poster Presentation at AACR 2022

Thierry Guillaudeux, PhD, EVP, Research & Development at Kineta;  American Association for Cancer Research (AACR) Annual Meeting 2022;  CD27 a new immuno-oncology target shaping innate and adaptive anti-tumor immune responses poster; April 13, 2022

 

Kineta CD27 Poster Presentation at ESMO Immuno-Oncology Congress 2021

Thierry Guillaudeux, PhD, Vice President Immuno-oncology at Kineta;  European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2021;  Novel fully human agonist antibodies against the T-cell costimulatory receptor CD27shape adaptive anti-tumor immunity poster; December 8-11, 2021


Kineta CD27 Poster Presentation at SITC 2021

Thierry Guillaudeux, PhD, Vice President Immuno-oncology at Kineta;  Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting;  A promising cancer immunotherapy target: Novel agonistic human antibodies against the human T-cell costimulatory receptor CD27 poster; November 13, 2021










Kineta CD27 Poster Presentation at AACR 2021

Thierry Guillaudeux, PhD, Vice President Immuno-oncology at Kineta;  Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting;  A promising cancer immunotherapy target: Novel agonistic human antibody against the human T-cell costimulatory receptor CD27 poster; October 5-6, 2021